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Abstract
Background:  The therapeutic efficacy of artesunate plus amodiaquine and artemether/
lumefantrine were assessed in an area of Nigeria with high levels of Plasmodium falciparum resistance
to chloroquine and sulphadoxine-pyrimethamine.
Participants:  Children aged 6 to 59 months with uncomplicated P. falciparum infection and
parasite density 1,000 to 200,000 parasites/µL enrolled following informed consent by parents.
Methods: Eligible children were randomly assigned to receive either a 3-day course of artesunate
(4 mg/kg) plus amodiaquine (10 mg/kg) or 6-dose course of artemether/lumefantrine (20/120 mg
tablets) over three days. Patients were followed up with clinical and laboratory assessments until
day 14 using standard WHO in-vivo antimalarial drug test protocol.
Results: A total 119 eligible children were enrolled but 111 completed the study. Adequate clinical
and parasitological response (ACPR) was 47 (87.0%) and 47 (82.5%) for artemether-lumefantrine
(AL) and artesunate+amodiaquine (AAMQ) respectively (OR 0.7, 95% confidence interval 0.22 to
2.22). Early treatment failure (ETF) occurred in one participant (1.8%) treated with AAQ but in
none of those with AL. Two (3.7%) patients in the AL group and none in the AAQ group had late
clinical failure. Late parasitological failure was observed in 9 (15.8) and 5 (9.3%) of patients treated
with AAQ and AL respectively. None of participants had a serious adverse event.
Conclusion:  Artemether-lumenfantrine and artesunate plus amodiaquine have high and
comparable cure rates and tolerability among under-five children in Calabar, Nigeria.
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Background
Malaria accounts for more than one million deaths of
mostly African children yearly. Early detection and
prompt treatment is a key component of the global strat-
egy for malaria control [1]. Across Africa, Plasmodium fal-
ciparum  resistance to common affordable antimalarial
drugs, chloroquine and sulphadoxine-pyrimethamine has
reached very high levels, and noticably hampered malaria
control efforts in the region [2]. In Nigeria, chloroquine
and sulphadoxine-pyrimethamine have been the first and
second line anti-malaria drugs respectively but evidence
from local research spanning a period of two decades
show that the therapeutic efficacy of these two drugs have
deteriorated due to high levels of P. falciparum resistance
in all parts of the country [3-5].
The World Health Organization recommends that combi-
nation treatment rather than monotherapy should be
used in areas where multi-drug resistance to P. falciparum
is a problem [6]. Combination drugs act at different sites
or have different mechanisms of action, achieve better
cure rates and are more likely to delay development of
parasite resistance [7,8]. Artemisinin-based combination
treatments (ACTs) are preferred because artemisinin com-
pounds have rapid parasite and fever clearance effects and
also reduce gametocyte rate with the potential to reduce
transmission. Artemisinin derivatives have short half life
but the component combination drug, with a longer dura-
tion of action, makes up for this by providing sustained
activity to eliminate remaining parasites[7].
The artemisinin-based combination treatment regimens
are more expensive than each drug used singly, but their
advantages over monotherapy far outweigh the cost.
Artemisinin-based combination treatments are recom-
mended for use as first-line treatment for uncomplicated
malaria, even in resource-poor areas where multi-drug
resistant P. falciparum infection is a problem [6]. ACTs
have been used for a long time as first-line treatment in
some South-East Asian countries [9,10].
The options under consideration in Nigeria for ACTs are
amodiaquine with artesunate, or artemether-lumefan-
trine. Artemether-lumefantrine has reportedly high cure
rates in observational studies, but controlled trials com-
paring it against other artemisinin containing regimens
are few [11]. It has an advantage that the component
drugs are coformulated in the same tablet but it is expen-
sive, even at discounted rates, and requires patients to take
six doses. Amodiaquine plus artesunate is less expensive,
but not co-formulated, and therefore more likely to be
misused as monotherapy. It is believed that cure rates of
this combination regimen may be lower than with arte-
mether-lumefantrine because of parasite resistance to
amodiaquine.
The Nigerian government supported randomized control-
led trials in the six geopolitical zones of the country to
assess the clinical efficacy and parasitological response of
P. falciparum to combinations of artemether/lumefantrine
and artesunate plus amodiaquine in treating uncompli-
cated childhood malaria. This paper describes one of
these trials, conducted in the far-south geo-political zone
within the Niger Delta region of the country. P. falciparum
resistance to chloroquine was first documented in this
region in 1987 and the current rate of resistance to chlo-
roquine and sulphadoxine-pyrimethamine (SP) exceeds
80% [3,12].
Methods
Study area and population
This study was conducted in Ikot Ansa a rural community
within the Calabar Municipal Local Council area of Cross
River State, Nigeria. The area has a projected population
of 222,100, with 44,420 being under five years of age. This
area lies within the tropical rainforest belt of southeastern
Nigeria. The annual rainfall is 2,000–3,000 mm, within
the rainy season lasting from April to October. There are
two predominant ethnic groups, Efiks and Ejagham. The
people's main occupations are subsistence farming, fish-
ing and logging. Malaria is holoendemic in the study area
with high and perennial transmission, especially in the
rainy season (from April to November). The study was
conducted in the months of September, October and
November, 2004.
Patient enrolment
Children were enrolled if they had uncomplicated
malaria, and fulfilled the following inclusion criteria: res-
idence in study area, age 6–59 months, axillary tempera-
ture  ≤37.5°C and parasite density of 1,000–200,000
asexual parasites/µl of blood, and informed consent by
parents/guardian. Children with packed cell volume
(PCV) <15%, severe malnutrition, other signs of severe
malaria or illness including any "danger sign" (viz. inabil-
ity to drink or breastfeed, vomiting everything, recent his-
tory of convulsion, lethargy or unconsciousness, inability
to sit or stand up, were excluded from the study [12].
Ethical approval was given by the University of Calabar
Teaching Hospital Ethical Committee. A written informed
consent was obtained from each parent/legal guardian of
eligible participants prior to enrolment.
Randomization
Participants were randomized by simple random sam-
pling technique (drawing lots) in blocks of ten (10) to
receive either artemether-lumefantrine (AL) or artesu-
nate+amodiaquine. Allocation sequence was concealed in
opaque, sealed and serially numbered envelopes. Study
treatment was started on the day of randomization (dayMalaria Journal 2006, 5:43 http://www.malariajournal.com/content/5/1/43
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zero) and completed on day two, while follow-up contin-
ued for 14 days. Clinical examination plus body weight
and height were recorded on day zero. Follow-up visits
were scheduled on days 1, 2, 3, 7 and 14. On each visit,
clinical examination including axillary temperature and
thick blood film specimen obtained to screen for presence
of malaria parasites and density was assessed by light
microscopy. Packed cell volume (PCV) was estimated on
day zero and repeated on day 14.
Interventions
Artesunate and amodiaquine were given orally at 4 mg/kg
and 10 mg/kg body weight respectively, once daily on
days 0, 1 and 2 with amodiaquine reduced to 5 mg/kg on
day 2. Artemether/lumefantrine was given as 20/120 mg
tablets. Participants weighing 5–14 kg received one tablet
(20/120 mg), two tablets (40/240 mg) for body weight
1524 kg and three tablets for those weighing 25 – 35 kg.
Each participant had a total of six doses of AL, with each
dose at 12-hourly intervals for 3 days. Treatment was
directly supervised by the research nurse and patients
observed for 30 minutes. Drugs were re-administered to
those who vomited within this period. Tepid sponging,
exposure and administration of paracetamol at 15 mg/kg
body weight were used to reduce high fever. Participants
that did not return on schedule for follow-up were visited
at home on the same day.
Laboratory investigation
Thick and thin blood smears were prepared and stained in
3% Giemsa solution for 30 minutes. The smears were read
to 100 fields with quantification of P. falciparum asexual
parasitaemia on the thick smear. Parasites were enumer-
ated using thick film as described by Shute [14]. The par-
asite density (per µl of blood) was calculated, assuming a
normal leucocyte level of 8,000/µl. The thin film was used
to speciate the parasites. Packed Cell Volume (PCV) was
measured on days 0 and 14 with sample collected in a
heparinized capillary tube and centrifuged for 5 minutes
at 10,000 G.
Analysis
Data generated were recorded in a log book, and individ-
ual patients case record files. Data were entered and ana-
lyzed with EPI-Info version 6.4. Data were also exported
to SPSS version 11.0 for further analysis. Differences
between groups were assessed using chi-square (X2), 't'
test for continuous normally distributed variables and
nonparametric Kruskal-Wallis was used to compare con-
tinuous not normally distributed variables.
Therapeutic efficacy was determined on day 14 or earlier
by assessing both clinical and parasitological response
based on the WHO guidelines for assessing therapeutic
efficacy [15]. The classification of treatment based on this
protocol is shown on Figure 1.
Results
Patients
A total of 594 children were screened and 119 eligible
ones were enrolled. The trial profile (Figure 2) shows the
pattern and reasons for exclusion and losses to follow up.
A total of six (10.0%) and two (3.4%) were respectively
lost to follow-up in the artesunate/lumefandtrine (AL)
and the artesunate/amodiaquine (AAMQ) groups. The AL
arm had 60 participants, while the AAMQ arm had 59. A
total of 54 participants who received AL and 57 who
received AAMQ completed the trial, and had adequate
data for the analysis of the end-points. Table 1 shows the
baseline characteristics of the eligible participants. The
two treatment groups were comparable in all characteris-
tics. Data on previous antimalarial drug-use pattern shows
that 11 (9.2%) of the enrolled participants had used anti-
malarial drugs in the past two weeks. The majority of these
(8/11; 72.7%) had used chloroquine.
Outcomes
Table 2 shows the results of the 14-day therapeutic effi-
cacy of the drugs. The number of evaluable participants
with adequate clinical and parasitological response
(ACPR) were 47 (87.0%) and 47 (82.5%) for AL and
AAMQ, respectively. The difference in the cures rates of
the two regimens was not statistically significant (Odds
ratio 0.7, 95% confidence interval 0.22 to 2.22). Early
treatment failure (ETF) was observed in one participant
Classification of malaria treatment outcome Figure 1
Classification of malaria treatment outcome.
Early Treatment Failure (ETF) was defined as development of danger signs or 
severe malaria on days 1,2 or 3 in the presence of parasitaemia, or parasitaemia on 
day 2 higher than day 0 count irrespective of axillary temperature, or parasitaemia on
day 3 with axillary temperature￿ 37.5
oC, or parasitaemia on day 3> 25% of day 0 
count irrespective of axillary temperature.
Late Clinical Failure (LCF) as development of danger signs or severe malaria and/or
axillary temperature ￿ 37.5
oC on any day from day 4 to 14 in the presence of 
parasitaemia without previously meeting any of the criteria of ETF.
Late Parasitological Failure (LPF) as presence of parasitaemia on day 14 and
axillary temperature < 37.5
oC without previously meeting any of the criteria of ETF
or LCF.
Adequate Clinical and Parasitological Response (ACPR) as absence of 
parasitaemia on day 14 irrespective of axillary temperature without previously
meeting any of the criteria of ETF, LCF, LPF.Malaria Journal 2006, 5:43 http://www.malariajournal.com/content/5/1/43
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(1.8%) that received AAMQ but in none of those treated
with AL.
Figure 3 shows that both treatment regimens had rapid
and comparable fever clearance rates. One participant that
received AAMQ had pains in the ear, which resolved
before day 14. No other adverse events were observed in
either treatment groups.
Discussion
The key goal of artemisinin-based combination treatment
(ACT) is to enhance cure rates and delay development of
parasite resistance to component drugs [16]. This study
has shown rapid parasite and fever clearance in children
treated with 6-dose regimen of artemether-lumefantrine
(AL) and 3-day course of artesunate plus amodiaquine
(AAMQ). This is characteristic of artemisinin combina-
tion therapy [6]. It was also demonstrated that these ACT
regimens were tolerable among under-five children in this
locality. The ACTs were not compared with existing first-
line and second-line drugs for uncomplicated malaria
(chloroquine or sulphadoxine-pyrimethamine,) because
of very high treatment failures (in excess of 80%) recently
reported for both drugs in the study area [12]. Administer-
ing such ineffective treatments to ill, under-five children
could significantly increase the risk of poor treatment out-
come.
The cure rates obtained for a 6-dose regimen of AL and a
3-day course of AAMQ were high (> 80%) but fell short of
therapeutic efficacy levels reported in other areas. Day-14
cure rates for AAMQ were 91%, 93%, and 98% in Kenya,
Senegal and Gabon, with lower day-28 cure rates of 68%,
82% and 85%, respectively [17]. Another report of 14-day
in-vivo study of AAMQ in Mozambique showed a parasi-
tological cure rate of 94.3% [8].
The 14-day cure rate obtained for a 6-dose regimen of AL
in the present study is comparable with those reported for
4-dose regimen in other trials, but lower than cure rates
obtained in other 6-dose trials [9,11]. A 42-day cure rate
of 93.6% has been documented in a recent randomized
controlled trial of 6-dose regimen of AL [18].
This study has demonstrated comparable therapeutic effi-
cacy and tolerability for a 6 dose regimen of artemether-
lumefantrine and a 3-day course of artesunate plus amo-
diaquine. This apparent lack of difference in effects may
be because the study samples were small and lacked statis-
tical power to detect significant difference at 95% confi-
dence level.
The short follow-up period of 14 days is another method-
ological limitation of this study. Recent observations have
shown that treatment failures affecting artemisininbased
combination treatment regimens tend to occur after 21
days [19]. The minimum follow-up period currently rec-
ommended this type of studies is 28 days. This trial started
before the evidence that 14-day follow-up period is inad-
Table 1: Baseline characteristics of participants
Characteristics Mean (SD) Artesunate + amodiaquine (N = 59) Artemether-lumefantrine (N = 60) Test statistics*
Age in months 29.1 (17.1) 28.2(16.2) 0.43†
Sex (Male) ‡: 28 (47.5) 33 (55.0) 0.68‡
Weight in Kg 12.4(3.8) 12.3(3.0) 0.59†
Height in cm (SD) 86.7(13.7) 85.6(12.7) 0.64†
Packed cell volume Day-0 28.8 (4.9) 28.9 (4.5) 0.32†
Packed cell volume Day-14 33.3 (3.6) 33.6 (4.0) 0.43†
Axillary temperature (°C) 38.5 (0.96) 38.6(0.81) 0.87†
Geometric mean parasite density in µL(range) 7972.0 (1,000 to 258,824) 7972.3 (1,011 to 318,769) 0.73§
‡Frequency (%) and Chi-squared test; †t-test; §Kruskal-Wallis H test;
*All tests show that both study groups were not statistically significant different.
Trial Profile Figure 2
Trial Profile.
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equate for in-vivo efficacy studies of ACTs became over-
whelming.
The Nigerian government has reviewed the malaria treat-
ment policy, replacing chloroquine and sulphadoxine-
pyrimethamine with artemisinin-based combination
treatment (ACT) as the first-line treatment for uncompli-
cated malaria. This change in policy has been informed by
evidence from local studies like the one reported here
[20]. Larger effectiveness studies with higher statistical
power than the present study will be needed to ascertain
the effects of these drug combinations in this area. Pro-
spective sentinel monitoring of the use and effectiveness
of the new ACTs at strategic geographical locations in the
country would provide reliable evidence for health plan-
ning and future policy reviews.
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